No âmbito do Memorandum of Understanding, celebrado entre a Agência de Investigação Clínica e Inovação Biomédica (AICIB) e a European Organisation for Research and Treatment of Cancer (EORTC), partilhamos a lista de ensaios clínicos em Oncologia, em desenvolvimento, e abertos à oportunidade de realização em Portugal. As datas apresentadas nos questionários seguintes encontram-se desatualizadas, podendo os mesmos ser preenchidos à data atual.
Nova adição:
Estudo: EORTC-2334-BTG (até 10/01/2024)
Status: pré-exequibilidade (pre-feasibility)
Título: LUMEN-1 study entitled “177Lu-DOTATATE for recurrent meningioma: a randomized phase II study”
Link: https://eortc.wufoo.com/forms/z188ayvc17y5nsw/
Anteriores:
Estudo: 2022-MG ATOM (nova data 01/11/2023)
Status: Exequibilidade (feasibility)
Título: Adjuvant Tebentafusp (IMCgp100) versus observation in HLA-A*02:01 positive patients following definitive treatment of high-risk uveal melanoma (UM): a randomized Phase III study
Link: https://eortc.wufoo.com/forms/z40jdb414fv8cx/
Estudo: 2029-LCG ICARS (nova data 31/10/2023)
Status: Exequibilidade (feasibility)
Título: Immunotherapy Conso After Radical treatment of Synchronous Oligo-metastatic NSCLC
Link: https://eortc.wufoo.com/forms/site-feasibility-part-1-eortc-2029lcg-aicarsa/
Estudo: 2237-BCG-QLG
Status: Exequibilidade (feasibility)
Título: Improvement of Quality of Life through supportive treatments for hormone therapy – related symptoms I women with early Breast cancer; A pragmatic randomized Controlled Trial
Link: https://eortc.wufoo.com/forms/z1iczu2x0l4o5gs/
Estudo: 2257-BCG OPTIMAL
Status: Exequibilidade (feasibility)
Título: DE-escalation of (neo)Adjuvant systemic therapy in early triple-negative breast cancer patients with high Stil
Link: https://eortc.wufoo.com/forms/z9tc5g61wr8dmp/
Estudo: 2329-LG AML22
Status: pré-exequibilidade (pre-feasibility)
Título: Novel BCL-2 inhibitor sonrotoclax in combination with 10-day ASTX727 compared to induction chemotherapy in fit, sixty years of age or older, FLT3 wild-type, ELN intermediate or adverse risk, newly diagnosed, de novo AML patients : a randomized phase II study of the EORTC Leukemia Group and GIMEMA
Link: https://eortc.wufoo.com/forms/z1wm24um0hupmyb/
Estudo: 2338-BCG (elderly)
Status: pré-exequibilidade (pre-feasibility)
Título: Benefit of Neoadjuvant treatment in older patients with TNBC, HER2+ and luminal breast cancer
Link: https://eortc.wufoo.com/forms/z12umdp70m3udqt/
Estudo: 2357-GUCG CLEVER
Status: pré-exequibilidade (pre-feasibility)
Título: A multicenter, Open-label, single-arm, Phase 2 Trial to Assess the Efficacy and Safety of Lenvatinib and EVERolimus in First-Line Treatment of Subjects with Advanced Chromophobe Renal Cell Carcinoma
Link: https://eortc.wufoo.com/forms/z15ffqtb0eiuqtk/
Estudo: 2379-GUCG MINERVA
Status: pré-exequibilidade (pre-feasibility)
Título: Single-Dose Intravesical Instillation of Chemotherapy After Ureteroscopy for Upper Tract Urothelial Carcinoma in the Prevention of Intravesical Recurrence: Phase III, Prospective randomized multicenter trial
